Pfizer has fended off Nova Nordisk for control of the next-gen weight-loss drug developer Metsera. Meanwhile, Resmed watches ...

Pfizer won its fight to buy obesity-drug maker Metsera, with an extra $1.7 billion and a little help from the Trump administration. Pfizer Inc. pulled off a comeback win, beating out Danish drug giant ...

You cannot know the power of an investment unless you see the returns. Many think of dividend stocks as a way of generating ...

Medicare beneficiaries will soon be able to get obesity and Type 2 diabetes drugs for a $50 copay. But there are some ...

Pfizer’s PFE third-quarter revenue fell 6%, as acquisition charges outweighed cost efficiencies and pushed adjusted diluted ...

Novo Nordisk is raising the stakes in its push to outbid rival Pfizer and acquire the development-stage drugmaker ...

The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after federal regulators narrowed r ...

The clinical trials report on Hemophilia A highlights opportunities in optimizing trial locations, enhancing cost-efficiency, and strategizing investments by offering insights into trial distributions ...

The intervention being tested is PF-07899895, an experimental drug administered in ascending oral doses. The purpose is to assess its safety and pharmacokinetics compared to a placebo.

Pfizer's oncology portfolio has produced a second positive phase 3 trial in HER2-positive breast cancer in the span of about a year. This time, the drug that delivered the positive readout is Tukysa, ...

Pfizer Inc. has re-entered the obesity drug sector by acquiring Metsera, Inc., having successfully outmaneuvered six other bidders. Despite skepticism over Pfizer's recent acquisitions, Metsera's ...

This is read by an automated voice. Please report any issues or inconsistencies here. President Trump’s deal with Pfizer on drug prices won’t do much for American patients, but it’s great for Pfizer.